Extended-release Buprenorphine as a Novel Low-dose Induction Strategy
Phase 2
30
about 9 months
18+
1 site in MA
What this study is about
This trial is testing extended-release buprenorphine (XR-BUP) as a new way to start treatment for opioid use disorder. Participants will receive fentanyl to prevent withdrawal symptoms, followed by an injection of XR-BUP and monitoring for any withdrawal effects.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Extended-release Buprenorphine
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
buprenorphine
sublingual
Primary: Plasma-concentration curves (AUC) of buprenorphine., Safety and tolerability of XR-Buprenorphine
Secondary: Elimination half-life
Psychiatry / Mental Health